Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery

Phase 3

Terminated

Conditions: Intraoperative Bleeding

Interventions: Device: Gelfoam Plus
Device: BioFoam Surgical Matrix

Registration Number: NCT01458561

Lead Sponsor: CryoLife, Inc.

Brief Summary: This is a prospective, multicenter, randomized, controlled investigation. Subjects in which bleeding from the exposed parenchymal surface is observed intraoperatively following the ligature of vessels visible with the unaided eye will be randomized to an adjunctive application of BioFoam or a standard topical hemostatic agent (Gelfoam with thrombin, in the form of Gelfoam Plus) to the entire exposed parenchymal surface. Following primary treatment of the exposed parenchymal surface as prescribed by the randomization scheme, treatment sites will be visually evaluated for the continued presence of bleeding. The overall objective of this investigation is to collect clinical data concerning the safety and effectiveness of BioFoam used as an adjunct to conservative measures of achieving hemostasis, such as manual pressure, cautery, and ligation, for intraoperative capillary, arteriolar, and venular bleeding (5 second stack of 5 gauze surface "Bleeding Score" = 1b or 2, score to be validated) on newly resected liver parenchyma in hemodynamically stable (American College of Surgeons' Advanced Trauma Life Support Class I Hemorrhage) and non-coagulopathic patients in the open treatment of exposed liver parenchyma versus a standard topical hemostatic agent, Gelfoam Plus. It is not intended for traumatic liver injury. The investigation will be conducted at a maximum of three investigational sites.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 1

Inclusion Criteria

Subject is undergoing an elective liver resection procedure that requires treatment of the exposed parenchymal surface due to the intraoperative presence of blood following ligature of vessels visible with the unaided eye;
Subject has adequate hepatic function as indicated by a Model for End-Stage Liver Disease (MELD) score of <10 at ≤30 days and at ≤7 days prior to surgery;
Subject has adequate hemostatic function identified as an international normalized ratio (INR), platelet count, and activated clotting time within the central laboratory's normal reference range;
Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation; and
Subject is ≥ 18 years of age.

Preoperative

Exclusion Criteria

Subject with known or suspected sensitivity to products of bovine origin
Subject with known or suspected sensitivity to glutaraldehyde
Subject with active infection (either systemic or in the treatment region) or hepatic cysts due to parasitic disease and/or abscesses due to bacterial and/or amebic disease;
Subject with abnormal calcium metabolism identified as values for ionized calcium and serum calcium corrected for serum albumin that are outside of the central laboratory's normal reference range;
Subject with abnormal renal status identified as an estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), serum creatinine, sodium, chloride, potassium, and/or bicarbonate values that are outside of the central laboratory's normal reference range;
Subject with hyperparathyroidism identified as an intact parathyroid hormone level >72 pg/mL, serum calcium >10.6 mg/dL, and phosphate <2.4 mg/dL, and, for secondary or tertiary hyperparathyroidism only, alkaline phosphatase >147 U/L
Subject with a pancreatic amylase and/or lipase value outside of the central laboratory's normal reference range;
Subject with blunt and/or penetrating liver trauma;
Subject diagnosed with any coagulation disorder;
Subject whose life-expectancy is less than that required for the prescribed follow-up duration;
Subject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product;
Subject with any surgical implant that would interfere with necessary follow-up imaging;
Subject who is pregnant (as confirmed by a urine pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding;
Subject who is undergoing concomitant procedures other than (1) cholecystectomy, (2) umbilical hernia repair, or (3) uncomplicated colon resection (i.e., no significant spillage);
Subject who is immunocompromised;
Subject with an American Society of Anesthesiologist (ASA) Score >2
Subject with a MELD score of ≥10 at ≤30 days or at ≤7 days prior to surgery;
Subject diagnosed with an autoimmune disease; and
Subject in whom the surgeon intends to use adhesion prevention products.
Subject who is returning to the operating room (OR) to address a complication associated with a liver resection, including but not limited to hematoma evacuation and biliary leak.

Intraoperative Inclusion Criterion:

Subject in whom bleeding (assignment of a "Bleeding Score" of 1 or 2) from the exposed parenchymal surface after ligature of vessels visible with the unaided eye and removal of any clamps used for hemostasis is observed

Intraoperative Exclusion Criterion:

Subject in whom any major intraoperative bleeding incidences during the resection procedure occurred (i.e., subject with assignment of an American College of Surgeons Advanced Trauma Life Support Hemorrhage Class of II, III, or IV Hemorrhage)

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Gelfoam Plus	Gelfoam Plus	Control of bleeding using Gelfoam Plus as a surgical adjunct
BioFoam Surgical Matrix	BioFoam Surgical Matrix	Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct

Primary Outcome Measures

Name	Time	Method
Time to Achieve Intraoperative Hemostasis Following Open Liver Resection Surgery in Subjects Receiving an Application of BioFoam or a Standard Topical Hemostatic Agent	3 minutes following a single application of the prescribed hemostatic agent	Number of subjects achieving intraoperative hemostasis (y/n) at 3 minutes following a single application of the prescribed hemostatic agent

Secondary Outcome Measures

Name	Time	Method
Amount of Postoperative Fluid Loss	Time from drain insertion to drain removal (where applicable), average 24-72 hours postoperatively	Amount of fluid lost postoperatively \[measured between time of drain insertion (if applicable) to drain removal, average 24-72 hours postoperatively\]
Eval. for Presence of Device by MRI w/ & w/Out Contrast, & Diagnose/Eval. Abdominal Fluid Collection/Biliary Leak, Residual Scarring, Hepatic Regeneration, & Assess for Emergence of Primary/Recurrent Malignancy by MRI w/ or w/Out Contrast as Appropriate	Within 48 hours postoperatively, up to 48 hours prior to hospital discharge (avg. 5-7 days postoperatively), and 30 days, 3 months, 6 months, 9 months, 1 year, and 2 years postoperatively
Time to Hemostasis	1, 3, 5, 7, and 10 minutes following application of prescribed hemostatic agent	Number of subjects achieving hemostasis \[by assessing for hemostasis (yes/no)\] at pre-determined time points: 1, 3, 5, 7, and 10 minutes following application of prescribed hemostatic agent. Time to hemostasis is recorded as the first of the predetermined time points to receive a "yes" assessment.
Achievement of Immediate Hemostasis	1 minute after application of prescribed hemostatic agent	Number of subjects achieving hemostasis at 1 minute after application of prescribed hemostatic agent
Intraoperative Blood Loss	Time from initial application to confirmed achievement of hemostasis (eval. up to 10 minutes following application of hemostatic agent)	Amount of blood lost between time of initial application of prescribed hemostatic agent and confirmed achievement of hemostasis (achievement of hemostasis eval. out to 10 minutes following application of prescribed hemostatic agent)
Amount of Postoperative Bilious Drainage	Time from drain insertion to drain removal (where applicable), average 24-72 hours postoperatively
Amount of Intraoperative Blood Products Administered	Intraoperatively (throughout procedure, from initial skin cut to final wound closure, average 4-5 hours duration)	Amount of blood products administered intraoperatively (throughout procedure: from initial skin cut to final wound closure)
Duration of Drainage	Time between drain insertion and last recorded emptying time during hospitalization (where applicable), average 24-72 hours postoperatively	Total length of time between drain insertion and last recorded emptying time during hospitalization (where applicable), average 24-72 hours postoperatively
Core Body Temperature	At the time of test or control article application (expected average 3-4 hours from skin cut)
Total Hospitalization Time	Hospital admission (day of surgery) until hospital discharge (average 5-7 days)	Length of time between hospital admission (day of surgery) and hospital discharge (average 5-7 days)
Subjects Requiring Additional Hospitalization/Surgical Intervention	Any hospitalization/surgical intervention following final wound closure through 2 year follow-up visit (average 2 yr duration)	Number of subjects requiring additional hospitalization/surgical intervention following final wound closure through the 2 year follow-up
Subject Laboratory Evaluations	Preoperatively through final 2 year follow-up	Number of laboratory evaluations outside of range from preoperative assessments through final 2 year follow-up
Total Time of Operative Procedure	Skin cut to skin closure (average 4-5 hour duration)
Number of Subjects Requiring Reoperation Due to Bleeding and/or Biliary Leakage (Reoperation Required? y/n)	After final wound closure through 2 year follow-up visit (average 2 yr duration)	Number of subjects requiring reoperation due to bleeding and/or biliary leakage out to 2 years postoperatively (reoperation required? y/n)
Evaluation of Anti-Bovine Serum Albumin (Anti-BSA) Antibody Titers	Preoperatively (up to 30 days before surgery), immediately post-application of hemostatic agent (within minutes), within 48 hrs postoperatively, up to 48 hrs before hospital discharge, at 7-10 days, 30 days, 3 mos, 6 mos, 9 mos, 1 yr, and 2 yr postop	Evaluation of anti-BSA antibody titers to determine number of subjects/participants with a positive titer at various time points
Number of Procedure Complications and/or Adverse Events	Through final follow-up (2 years postoperatively)

Trial Locations

Locations (2): Stanford University Medical Center
🇺🇸
Palo Alto, California, United States
Swedish Medical Center
🇺🇸
Seattle, Washington, United States